Devalued and distrusted: can the pharmaceutical industry restore its broken image?
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hoboken, N.J.
Wiley
2013
|
| Schlagworte: | |
| Beschreibung: | Includes bibliographical references and index "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- |
| Beschreibung: | ix, 125 p. |
| ISBN: | 9781118511299 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044171741 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170217s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 9781118511299 |c Online |9 978-1-118-51129-9 | ||
| 035 | |a (ZDB-30-PAD)EBC1104475 | ||
| 035 | |a (ZDB-89-EBL)EBL1104475 | ||
| 035 | |a (OCoLC)831464032 | ||
| 035 | |a (OCoLC)823389919 | ||
| 035 | |a (DE-599)BVBBV044171741 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 338.4/76151 |2 23 | |
| 100 | 1 | |a LaMattina, John L. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Devalued and distrusted |b can the pharmaceutical industry restore its broken image? |c John L. LaMattina |
| 264 | 1 | |a Hoboken, N.J. |b Wiley |c 2013 | |
| 300 | |a ix, 125 p. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- | ||
| 505 | 0 | |a Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts | |
| 650 | 4 | |a Pharmaceutical industry |x Corrupt practices | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Paperback |z 978-1-118-48747-1 |
| 912 | |a ZDB-30-PAD |a ZDB-30-PBE | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029578586 | ||
Datensatz im Suchindex
| _version_ | 1804177290193534976 |
|---|---|
| any_adam_object | |
| author | LaMattina, John L. |
| author_facet | LaMattina, John L. |
| author_role | aut |
| author_sort | LaMattina, John L. |
| author_variant | j l l jl jll |
| building | Verbundindex |
| bvnumber | BV044171741 |
| collection | ZDB-30-PAD ZDB-30-PBE |
| contents | Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts |
| ctrlnum | (ZDB-30-PAD)EBC1104475 (ZDB-89-EBL)EBL1104475 (OCoLC)831464032 (OCoLC)823389919 (DE-599)BVBBV044171741 |
| dewey-full | 338.4/76151 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 338 - Production |
| dewey-raw | 338.4/76151 |
| dewey-search | 338.4/76151 |
| dewey-sort | 3338.4 576151 |
| dewey-tens | 330 - Economics |
| discipline | Wirtschaftswissenschaften |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02307nmm a2200361zc 4500</leader><controlfield tag="001">BV044171741</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170217s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118511299</subfield><subfield code="c">Online</subfield><subfield code="9">978-1-118-51129-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-30-PAD)EBC1104475</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-89-EBL)EBL1104475</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)831464032</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)823389919</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044171741</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">338.4/76151</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">LaMattina, John L.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Devalued and distrusted</subfield><subfield code="b">can the pharmaceutical industry restore its broken image?</subfield><subfield code="c">John L. LaMattina</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">Wiley</subfield><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">ix, 125 p.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"--</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmaceutical industry</subfield><subfield code="x">Corrupt practices</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Paperback</subfield><subfield code="z">978-1-118-48747-1</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-PAD</subfield><subfield code="a">ZDB-30-PBE</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029578586</subfield></datafield></record></collection> |
| id | DE-604.BV044171741 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:45:43Z |
| institution | BVB |
| isbn | 9781118511299 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029578586 |
| oclc_num | 831464032 823389919 |
| open_access_boolean | |
| physical | ix, 125 p. |
| psigel | ZDB-30-PAD ZDB-30-PBE |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Wiley |
| record_format | marc |
| spelling | LaMattina, John L. Verfasser aut Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina Hoboken, N.J. Wiley 2013 ix, 125 p. txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts Pharmaceutical industry Corrupt practices Erscheint auch als Druck-Ausgabe, Paperback 978-1-118-48747-1 |
| spellingShingle | LaMattina, John L. Devalued and distrusted can the pharmaceutical industry restore its broken image? Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts Pharmaceutical industry Corrupt practices |
| title | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_auth | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_exact_search | Devalued and distrusted can the pharmaceutical industry restore its broken image? |
| title_full | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina |
| title_fullStr | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina |
| title_full_unstemmed | Devalued and distrusted can the pharmaceutical industry restore its broken image? John L. LaMattina |
| title_short | Devalued and distrusted |
| title_sort | devalued and distrusted can the pharmaceutical industry restore its broken image |
| title_sub | can the pharmaceutical industry restore its broken image? |
| topic | Pharmaceutical industry Corrupt practices |
| topic_facet | Pharmaceutical industry Corrupt practices |
| work_keys_str_mv | AT lamattinajohnl devaluedanddistrustedcanthepharmaceuticalindustryrestoreitsbrokenimage |